newsonline24

Turning clinical data into oncology evidence

Korea University Anam Hospital is one of South Korea’s leading academic medical centers, with particular experience in the treatment of colorectal and breast cancer. Through this partnership, KUAH and Data4Life will standardize KUAH’s clinical oncology datasets to the Observational Medical Outcomes Partnership (OMOP) Common Data Model, making them interoperable, research-ready, and suitable for international federated studies.

At the center of the collaboration is the deployment of Data4Life’s Data2Evidence platform at KUAH, supporting the OMOP CDM conversion of existing clinical oncology datasets. The standardized data environment will allow KUAH’s research team to generate reproducible real-world evidence on treatment outcomes, disease trajectories, and care quality, and to conduct federated network studies alongside international academic partners. The collaboration will start with colorectal and breast cancer and expand research projects across other tumor types.

Open-source infrastructure for oncology evidence

Oncology research depends on access to large, high-quality, longitudinal datasets, yet much of the world’s most valuable clinical data remain siloed within single institutions, inaccessible for multi-site study or regulatory-grade evidence generation. This partnership is designed to close that gap at one of Korea’s premier cancer centers.

All research data generated through the collaboration will be structured using the OMOP CDM format and under a federated architecture that preserves patient privacy and institutional data sovereignty.

Dr. Ben M.W. Illigens, CEO, Data4Life

"Korea University Anam Hospital provides exceptional, long-term oncology care, resulting in deeply rich, longitudinal clinical data that capture the complete patient journey over years. By transforming these continuous source data into the globally recognized OMOP standard, we unlock their full potential. Together, we are ensuring that their invaluable, long-term clinical insights can seamlessly translate into standardized evidence that accelerates cancer research."